Zevra Therapeutics Inc (NASDAQ: ZVRA) has reported a loss for its third fiscal quarter (ending September 30) of $-0.40 versus a loss $-0.19 for the same period a year ago. This result fell short of the consensus estimate of $-0.30 by $-0.10. For the latest four quarters through September 30, E.P.S. were $-1.16 compared to $-1.02 a year ago.
Recent Price Action
On 11/7/23, Zevra Therapeutics Inc (NASDAQ: ZVRA) stock suffered a large decline of -3.5%, closing at $4.40. The stock has performed in line with the market over the last nine months and has risen 1.6% during the last week.
Current PriceTarget Research Rating
ZVRA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Zevra Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Zevra Therapeutics has a neutral Power Rating of 49 but a very low Appreciation Score of 3, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment